abstract |
GLUCAGON-LIKE PROTEIN-1 RECEPTOR AGONIST COMPOUNDS (GLP-1R). The present invention relates to glucagon-like protein 1 targeting compounds, which comprise glucagon-like protein 1 targeting linker conjugates linked to an antibody combining site. Various uses of the compounds are provided, including methods for the prevention or treatment of diabetes and conditions related to diabetes. |